Related Experiment Videos
Preleukemic proliferative changes in murine bone marrow after single and multiple 7,12-dimethylbenz(a)anthracene
H P Peterson1, A Feldges, K H von Wangenheim
1Institute of Medicine, Research Center Jülich GmbH, F.R.G.
Leukemia Research
|January 1, 1993
Summary
Multiple treatments with DMBA damage bone marrow stem cells, leading to lasting injury and compensatory proliferation. A single dose had no effect, but repeated exposure increases leukemia risk.
Area of Science:
- Hematology
- Toxicology
- Cancer Research
Background:
- Leukemia development involves complex changes in bone marrow cell kinetics.
- DMBA (7,12-dimethylbenz[a]anthracene) is a known carcinogen that can induce leukemia.
Purpose of the Study:
- To investigate the early kinetic parameter changes in murine bone marrow cells following DMBA treatment.
- To understand the impact of single versus multiple DMBA injections on hematopoietic stem cells (HSCs).
Main Methods:
- Mice received one, four, or eight i.p. injections of 1 mg DMBA biweekly.
- Measurements included CFU-S number, proliferation ability (PF), cell doubling time (td), and compartment ratio (CR) up to nine weeks post-injection.
Main Results:
- Multiple DMBA injections decreased CFU-S number and proliferation ability (PF).
- Multiple DMBA injections increased compartment ratio (CR) and cell doubling time (td), indicating stem cell injury and compensatory proliferation.
- A single DMBA injection showed no significant effect.
Conclusions:
- The first DMBA injection causes cytotoxic/genotoxic damage, stimulating proliferation but hindering HSC proliferation ability.
- Subsequent DMBA injections target proliferating HSCs, increasing the risk of proliferation control loss and terminal differentiation, potentially leading to leukemia.